11.88
-0.27 (-2.22%)
| 前收盘价格 | 12.15 |
| 收盘价格 | 11.87 |
| 成交量 | 1,353,681 |
| 平均成交量 (3个月) | 786,191 |
| 市值 | 922,024,704 |
| 价格/销量 (P/S) | 11.21 |
| 股市价格/股市净资产 (P/B) | 2.12 |
| 52周波幅 | |
| 利润日期 | 8 Apr 2025 - 14 Apr 2025 |
| 营业利益率 (TTM) | -340.67% |
| 稀释每股收益 (EPS TTM) | -2.60 |
| 季度收入增长率 (YOY) | 11.30% |
| 总债务/股东权益 (D/E MRQ) | 5.54% |
| 流动比率 (MRQ) | 6.26 |
| 营业现金流 (OCF TTM) | -191.72 M |
| 杠杆自由现金流 (LFCF TTM) | -106.56 M |
| 资产报酬率 (ROA TTM) | -31.08% |
| 股东权益报酬率 (ROE TTM) | -64.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Nurix Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.25 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.41% |
| 机构持股比例 | 111.85% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 34.00 (HC Wainwright & Co., 186.20%) | 购买 |
| 中 | 30.00 (152.53%) | |
| 低 | 16.00 (Morgan Stanley, 34.68%) | 保留 |
| 平均值 | 27.20 (128.96%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 12.57 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 15 Jul 2025 | 16.00 (34.68%) | 保留 | 12.15 |
| HC Wainwright & Co. | 14 Jul 2025 | 34.00 (186.20%) | 购买 | 12.69 |
| Oppenheimer | 10 Jul 2025 | 30.00 (152.53%) | 购买 | 12.67 |
| Stephens & Co. | 10 Jul 2025 | 30.00 (152.53%) | 购买 | 12.67 |
| UBS | 10 Jul 2025 | 26.00 (118.86%) | 购买 | 12.67 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合